At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Beta adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 03 Nov 1995 No-Development-Reported for Irritable bowel syndrome in France (Unknown route)
- 23 Feb 1995 Preclinical development for Gastrointestinal disorders in France (Unknown route)